Presbyopia IOL Panel Probes Concerns About Trial Sponsor Burdens
This article was originally published in The Gray Sheet
Executive Summary
Clinical trials of clear lens extraction (CLE) to treat presbyopia should strive for uncorrected distance visual acuity of 20/25 or 20/30 in 90%-95% of patients, members of FDA's Ophthalmic Devices Panel suggested at a March 5 meeting in Gaithersburg, Md
You may also be interested in...
CrystaLens Accommodating IOL First To Market; Firm Eyes Expanded Labeling
Eyeonics, Inc. will file a supplemental PMA for its CrystaLens AT-45 accommodating posterior chamber intraocular lens to broaden the treatment range beyond 1.0 diopter
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.